Valeritas Announces Second Quarter 2019 Financial Results
08 août 2019 16h05 HE
|
Valeritas, Inc.
BRIDGEWATER, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,...
Preclinical Study Shows Valeritas Proprietary h-Patch™ Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine
05 août 2019 07h00 HE
|
Valeritas, Inc.
- Parkinson’s Disease Therapeutic Apomorphine Delivery via the h-Patch™ Offers Advantages Over Subcutaneous Injections and Bulky Belt-worn Pump Devices - - Company Plans to Explore Partnering...
Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study
30 juil. 2019 07h00 HE
|
Valeritas, Inc.
- Company Plans to Explore Partnering Opportunities with CBD Therapeutics Companies - - Company to Host a Conference Call Today, July 30, 2019 at 11:00 AM ET - BRIDGEWATER, N.J., July 30, 2019 ...
Valeritas to Report Second Quarter 2019 Financial Results on August 8, 2019
22 juil. 2019 07h00 HE
|
Valeritas, Inc.
BRIDGEWATER, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,...
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population
08 juil. 2019 07h00 HE
|
Valeritas, Inc.
BRIDGEWATER, N.J., July 08, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced today...
Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device
27 juin 2019 07h00 HE
|
Valeritas, Inc.
BRIDGEWATER, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced it has...
Valeritas Announces Milestone of 20 Million V-Go® Insulin Delivery Devices Sold
24 juin 2019 07h00 HE
|
Valeritas, Inc.
BRIDGEWATER, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced today it...
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 when Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery
10 juin 2019 07h00 HE
|
Valeritas, Inc.
BRIDGEWATER, N.J., June 10, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced...
Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
31 mai 2019 16h05 HE
|
Valeritas, Inc.
BRIDGEWATER, N.J., May 31, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced that...
Valeritas to Participate in the American Diabetes Association’s 79th Scientific Sessions; Company Reiterates Second Quarter and Full-Year 2019 Revenue Guidance
29 mai 2019 07h00 HE
|
Valeritas, Inc.
BRIDGEWATER, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, announced today it will...